Adult: Neuro-Oncology Treatment

- Primary Central Nervous System Lymphoma (PCNSL)
  - Newly Diagnosed
  - Recurrent
    - IRB# 11601 Phase II study of maintenance obinutuzumab for primary central nervous system lymphoma Complete responders
    - IRB# 1012 Phase I/II study involving Carboplatin and Methotrexate administered with Blood-Brain Barrier opening, and Rituximab
    - No Trials Currently Available

- Glioma
  - Newly Diagnosed or Recurrent
    - High Grade Glioma
      - IRB# 922 Phase II study involving Carboplatin, cyclophosphamide, and etoposide phosphate administered intra-arterially; randomized to receive/not receive Delayed Intravenous Sodium Thiosulfate Chemoprotection
  - Recurrent
    - Anaplastic Oligodendroglioma or Oligoastrocytoma
      - IRB# 2868 Phase I/II study involving Carboplatin, Melphalan and Etoposide Phosphate administered with Blood-Brain Barrier opening and Delayed Intravenous Otoprotective Sodium Thiosulfate

- CNS Embryonal or Germ Cell Tumor
  - Newly Diagnosed
  - Recurrent or Refractory
    - No Trials Currently Available
    - IRB# 5056 Phase I/II study involving Melphalan and Carboplatin administered with Blood-Brain Barrier opening and Delayed Intravenous Otoprotective Sodium Thiosulfate

- New Diagnosed or Recurrent
  - IRB# 1012 Phase II study involving Carboplatin and Methotrexate administered with Blood-Brain Barrier opening, and Rituximab
  - IRB# 922 Phase II study involving Carboplatin, cyclophosphamide, and etoposide phosphate administered intra-arterially; randomized to receive/not receive Delayed Intravenous Sodium Thiosulfate Chemoprotection
  - IRB# 2868 Phase I/II study involving Carboplatin, Melphalan and Etoposide Phosphate administered with Blood-Brain Barrier opening and Delayed Intravenous Otoprotective Sodium Thiosulfate

- Recurrent
  - No Trials Currently Available

Key:
- Open for Enrollment
- In Development
- Enrollment on Hold

www.ohsu.edu/cancer

02/06/2017